Articles related to RESEARCH & CLINICAL TRIALS

In an adaptive randomized trial of adults with long COVID, fluvoxamine modestly reduced fatigue and improved quality-of-life scores through 90 days, while metformin findings remained inconclusive after dose modification and early termination.

Across three cohorts, molecular patterns in human milk were associated with maternal nutritional status, mammary biological signatures, and infant growth. Seven candidate biomarkers emerged, but their clinical utility and the proposed vitamin B5 mechanism remain unproven.

In SCRaTCH-OFO, live birth rates were 64% with endometrial scratching and 57% without it among patients with unexplained infertility and favorable natural-conception prognosis. The difference was not statistically significant, and enrollment fell short.

In a single-center randomized trial, mouth-dissolving clobazam and intranasal midazolam showed no statistically significant difference in clinical or electrographic seizure-termination time, supporting further study rather than establishing comparable efficacy.

Among individuals with progressive multiple sclerosis, higher blood neurofilament light chain (NfL) levels were associated with lower daily ambulatory activity, while increases in NfL over time tended to track with subsequent declines in step counts measured by wearable devices.

The FDA has approved tavapadon, a selective D1/D5 dopamine receptor partial agonist, for adults with Parkinson disease following phase 3 studies demonstrating benefit both as monotherapy in early disease and as adjunctive therapy to levodopa.